BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol 2015;60:575-89. [PMID: 26164735 DOI: 10.1016/j.survophthal.2015.06.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Sood AB, Angeles-Han ST. An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis. Curr Treatm Opt Rheumatol 2017;3:1-16. [PMID: 28944162 DOI: 10.1007/s40674-017-0057-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
2 Qiao D, He X, Wei C, Xia L, Bao L. Effects of Hyriopsis cumingii Polysaccharides on Mice Immunologic Receptor, Transcription Factor, and Cytokine. J Food Sci 2016;81:H1288-94. [PMID: 27061742 DOI: 10.1111/1750-3841.13288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
3 Tallouzi MO, Barry RJ, Bucknall N, Mathers JM, Murray PI, Calvert MJ, Moore DJ, Denniston AK; Cochrane Eyes and Vision Group. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012577] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Pepple KL, Wilson L, Van Gelder RN, Kovaleva M, Ubah OC, Steven J, Barelle CJ, Porter A. Uveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand. Transl Vis Sci Technol 2019;8:11. [PMID: 31588375 DOI: 10.1167/tvst.8.5.11] [Reference Citation Analysis]
5 Miraldi Utz V, Bulas S, Lopper S, Fenchel M, Sa T, Mehta M, Ash D, Lovell DJ, Kaufman AH. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr Rheumatol Online J 2019;17:79. [PMID: 31783768 DOI: 10.1186/s12969-019-0383-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
6 Liu F, Wang Y, Wang X, Zheng Y, Jin Z, Zhi J. Role of agonistic autoantibodies against type-1 angiotensin II receptor in the pathogenesis of retinopathy in preeclampsia. Sci Rep 2016;6:29036. [PMID: 27381670 DOI: 10.1038/srep29036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
7 Citirik M, Ucgul Atilgan C, Rahmanlar H, Alkan A, Gursoz H. Biological therapy for ocular Behçet's disease with off-label drug prescription in Turkey. Eur J Hosp Pharm 2021:ejhpharm-2021-002785. [PMID: 34083220 DOI: 10.1136/ejhpharm-2021-002785] [Reference Citation Analysis]
8 Kim M, Won J, Choi SY, Ju JH, Park Y. Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis–Related Uveitis. American Journal of Ophthalmology 2016;170:32-40. [DOI: 10.1016/j.ajo.2016.07.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
9 Li B, Li H, Zhang L, Zheng Y. Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2021;12:673984. [PMID: 33981245 DOI: 10.3389/fphar.2021.673984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jung J, Khachatryan N, Palestine A; Cochrane Eyes and Vision Group. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013818] [Reference Citation Analysis]
11 Ung L, Pattamatta U, Carnt N, Wilkinson-berka J, Liew G, White A. Oxidative stress and reactive oxygen species: a review of their role in ocular disease. Clinical Science 2017;131:2865-83. [DOI: 10.1042/cs20171246] [Cited by in Crossref: 55] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
12 Ratay ML, Bellotti E, Gottardi R, Little SR. Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation. Adv Healthc Mater 2017;6. [PMID: 29034584 DOI: 10.1002/adhm.201700733] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
13 Iwahashi C, Ono H, Haruta M, Minami T, Mashimo H, Shimojo H, Ohguro N. New onset or exacerbation of uveitis with infliximab: paradoxical effects? BMJ Open Ophthalmol 2019;4:e000250. [PMID: 31355342 DOI: 10.1136/bmjophth-2018-000250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sharon Y, Chu DS. Certolizumab pegol - Tumor necrosis factor inhibitor for refractory uveitis. Am J Ophthalmol Case Rep 2020;18:100633. [PMID: 32190782 DOI: 10.1016/j.ajoc.2020.100633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kramer M, Brichova M, Tugal-Tutkun I, Panchenko M, Gormezano N, Koenigsbauer F, Franco P, Muccioli C, Hasanreisoglu M; International EyeCOPE Study Group. Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study. Ophthalmol Ther 2021;10:565-80. [PMID: 34117983 DOI: 10.1007/s40123-021-00351-4] [Reference Citation Analysis]
16 Kowalski T, Mack HG. Ocular complications of tumour necrosis factor alpha inhibitors. Clin Exp Optom 2020;103:148-54. [PMID: 31077451 DOI: 10.1111/cxo.12904] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis. Acta Ophthalmol 2021. [PMID: 34532967 DOI: 10.1111/aos.15012] [Reference Citation Analysis]
18 Leal I, Romão VC, Mano S, Khmelinskii N, Campanilho-Marques R, Ponte C, Macieira C, Oliveira-Ramos F, Vieira-Sousa E, Rosa CM, Rodrigues W, Abegão Pinto L, Marques-Neves C, Fonseca JE. A Non-Infectious Uveitis Multidisciplinary Clinic in a Tertiary Referral Center: Clinical Impact and Added Value. J Multidiscip Healthc 2021;14:695-704. [PMID: 33790568 DOI: 10.2147/JMDH.S292981] [Reference Citation Analysis]
19 Kodati S, Weng CY. Current and Emerging Pharmaceutical Therapies for Noninfectious Uveitis. Int Ophthalmol Clin 2019;59:111-26. [PMID: 30585921 DOI: 10.1097/IIO.0000000000000253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Fabiani C, Vitale A, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Capozzoli M, Fusco F, Rana F, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol 2019;38:63-70. [PMID: 29611087 DOI: 10.1007/s10067-018-4069-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
21 M Castillejo Becerra C, Ding Y, Kenol B, Hendershot A, Meara AS. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmol 2020;5:e000331. [PMID: 32154367 DOI: 10.1136/bmjophth-2019-000331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 2017;36:183-9. [PMID: 27853889 DOI: 10.1007/s10067-016-3480-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
23 Generali E, Cantarini L, Selmi C. Ocular Involvement in Systemic Autoimmune Diseases. Clin Rev Allergy Immunol. 2015;49:263-270. [PMID: 26494481 DOI: 10.1007/s12016-015-8518-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
24 Ksiaa I, Abroug N, Kechida M, Zina S, Jelliti B, Khochtali S, Attia S, Khairallah M. Eye and Behçet's disease. Journal Français d'Ophtalmologie 2019;42:e133-46. [DOI: 10.1016/j.jfo.2019.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Bessette AP, Sharma S. Adalimumab for Noninfectious Uveitis. Ophthalmol Retina 2017;1:179-80. [PMID: 31047418 DOI: 10.1016/j.oret.2017.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Jung JH, Song GG, Kim JH, Choi SJ. The associations between interleukin 10 polymorphisms and susceptibility to autoimmune uveitis - a meta-analysis. Cent Eur J Immunol 2019;44:246-52. [PMID: 31933534 DOI: 10.5114/ceji.2019.89596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Weigelt CM, Fuchs H, Schönberger T, Stierstorfer B, Strobel B, Lamla T, Ciossek T, Bakker RA, Redemann NH. AAV-Mediated Expression of Human VEGF, TNF-α, and IL-6 Induces Retinal Pathology in Mice. Transl Vis Sci Technol 2021;10:15. [PMID: 34520511 DOI: 10.1167/tvst.10.11.15] [Reference Citation Analysis]
28 Ueda S, Akahoshi M, Takeda A, Inoue Y, Omoto A, Ayano M, Kimoto Y, Mitoma H, Arinobu Y, Niiro H, Tsukamoto H, Horiuchi T, Hikita SI, Fukuhara T, Ishibashi T, Sonoda KH, Akashi K. Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet's disease. Eur J Rheumatol 2018;5:9-15. [PMID: 30501852 DOI: 10.5152/eurjrheum.2017.17068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Buelens T, Ossewaarde-van Norel J, de Boer JH, Nubourgh I, Glibert G, Kamgang Semeu P, Fils JF, Caspers L, Postelmans L, Willermain F. EVALUATION OF TUMOR NECROSIS FACTOR INHIBITOR THERAPY IN SUSAC SYNDROME. Retina 2020;40:581-90. [PMID: 30707148 DOI: 10.1097/IAE.0000000000002466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
30 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Reference Citation Analysis]
31 Mashayekhi K, Sankian M, Haftcheshmeh SM, Taheri RA, Hassanpour K, Farnoosh G. A cross-linked anti-TNF-α aptamer for neutralization of TNF-α-induced cutaneous Shwartzman phenomenon: A simple and novel approach for improving aptamers' affinity and efficiency. Biotechnol Prog 2021;:e3191. [PMID: 34218531 DOI: 10.1002/btpr.3191] [Reference Citation Analysis]
32 Touhami S, Diwo E, Sève P, Trad S, Bielefeld P, Sène D, Abad S, Brézin A, Quartier P, Koné Paut I, Weber M, Chiquet C, Errera MH, Sellam J, Cacoub P, Kaplanski G, Kodjikian L, Bodaghi B, Saadoun D. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther 2019;19:477-90. [PMID: 30888881 DOI: 10.1080/14712598.2019.1595578] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
33 van der Horst-Bruinsma I, van Bentum R, Verbraak FD, Rath T, Rosenbaum JT, Misterska-Skora M, Hoepken B, Irvin-Sellers O, VanLunen B, Bauer L, Rudwaleit M. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open 2020;6:e001161. [PMID: 32371433 DOI: 10.1136/rmdopen-2019-001161] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
34 Liao H, Du S, Jiang T, Zheng M, Xiang Z, Yang J. UMSCs Attenuate LPS/D-GalN-induced Acute Liver Failure in Mice by Down-regulating the MyD88/NF-κB Pathway. J Clin Transl Hepatol 2021;9:690-701. [PMID: 34722184 DOI: 10.14218/JCTH.2020.00157] [Reference Citation Analysis]
35 Ozge G, Kucukevcilioglu M, Koylu MT. Comment on: "Autoimmune uveitis: clinical, pathogenetic, and therapeutic features". Clin Exp Med 2016;16:137-8. [PMID: 27052016 DOI: 10.1007/s10238-016-0415-4] [Reference Citation Analysis]
36 Crayne CB, Beukelman T. Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. Pediatr Clin North Am 2018;65:657-74. [PMID: 30031492 DOI: 10.1016/j.pcl.2018.03.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
37 Fernández-Vega B, Fernández-Vega Á, Rangel CM, Nicieza J, Villota-Deleu E, Vega JA, Sanchez-Avila RM. Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy? Case Rep Ophthalmol 2016;7:154-62. [PMID: 27065854 DOI: 10.1159/000445102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
38 Muñoz-Gallego A, Barral E, Enríquez E, Tejada P, Barceló A, de Inocencio J. Adalimumab for the treatment of refractory noninfectious paediatric uveitis. Int Ophthalmol 2017;37:719-25. [PMID: 27432171 DOI: 10.1007/s10792-016-0293-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
39 Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-kearney M, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Seminars in Arthritis and Rheumatism 2019;49:438-45. [DOI: 10.1016/j.semarthrit.2019.06.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
40 Çakar Özdal P. Behçet's Uveitis: Current Diagnostic and Therapeutic Approach. Turk J Ophthalmol 2020;50:169-82. [PMID: 32631005 DOI: 10.4274/tjo.galenos.2019.60308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1-55. [PMID: 29229445 DOI: 10.1016/j.preteyeres.2017.11.003] [Cited by in Crossref: 464] [Cited by in F6Publishing: 386] [Article Influence: 92.8] [Reference Citation Analysis]
42 Lin FL, Ho JD, Cheng YW, Chiou GCY, Yen JL, Chang HM, Lee TH, Hsiao G. Theissenolactone C Exhibited Ocular Protection of Endotoxin-Induced Uveitis by Attenuating Ocular Inflammatory Responses and Glial Activation. Front Pharmacol 2018;9:326. [PMID: 29686615 DOI: 10.3389/fphar.2018.00326] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
43 Shirinsky IV, Biryukova AA, Shirinsky VS. Simvastatin as an Adjunct to Conventional Therapy of Non-infectious Uveitis: A Randomized, Open-Label Pilot Study. Current Eye Research 2017;42:1713-8. [DOI: 10.1080/02713683.2017.1355468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
44 Ksiaa I, Abroug N, Kechida M, Zina S, Jelliti B, Khochtali S, Attia S, Khairallah M. Œil et maladie de Behçet. Journal Français d'Ophtalmologie 2019;42:626-41. [DOI: 10.1016/j.jfo.2018.09.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Leal I, Rodrigues FB, Sousa DC, Duarte GS, Romão VC, Marques-Neves C, Costa J, Fonseca JE. Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Med (Lausanne) 2019;6:104. [PMID: 31179280 DOI: 10.3389/fmed.2019.00104] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
46 Mercier AE, Ribeiro E, Korobelnik JF, Delyfer MN, Rougier MB. Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients. Ocul Immunol Inflamm 2018;26:477-84. [PMID: 27775458 DOI: 10.1080/09273948.2016.1236968] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
47 Maleki A, Anesi SD, Look-Why S, Manhapra A, Foster CS. Pediatric uveitis: A comprehensive review. Surv Ophthalmol 2021:S0039-6257(21)00143-0. [PMID: 34181974 DOI: 10.1016/j.survophthal.2021.06.006] [Reference Citation Analysis]
48 Fotiadou C, Lazaridou E. Psoriasis and uveitis: links and risks. Psoriasis (Auckl) 2019;9:91-6. [PMID: 31696050 DOI: 10.2147/PTT.S179182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
49 Cordero-Coma M, Calleja-Antolín S, Garzo-García I, Nuñez-Garnés AM, Álvarez-Castro C, Franco-Benito M, Ruiz de Morales JG. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies. Ophthalmology 2016;123:2618-25. [PMID: 27692527 DOI: 10.1016/j.ophtha.2016.08.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
50 Zhang R, Qian J, Li X, Yuan Y. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes. Br J Ophthalmol 2017;101:1731-8. [PMID: 28986343 DOI: 10.1136/bjophthalmol-2016-310044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
51 Kheir WJ, Mehanna C, Abdul Fattah M, Al Ghadban S, El Sabban M, Mansour AM, Hamam RN. Intravitreal Adalimumab for the Control of Breakthrough Intraocular Inflammation. Ocular Immunology and Inflammation 2018;26:1206-11. [DOI: 10.1080/09273948.2017.1335756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
52 Kheir V, Vaudaux J, Guex-crosier Y. Review of the latest systemic treatments for chronic non-infectious uveitis. Expert Review of Ophthalmology 2016;11:111-33. [DOI: 10.1586/17469899.2016.1153425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Radosavljevic A, Agarwal M, Bodaghi B, Smith JR, Zierhut M. Medical Therapy of Uveitic Macular Edema: Biologic Agents. Ocul Immunol Inflamm 2020;28:1239-50. [PMID: 32058830 DOI: 10.1080/09273948.2019.1709648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Mugheddu C, Atzori L, Del Piano M, Lappi A, Pau M, Murgia S, Zucca I, Rongioletti F. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther 2017;30. [PMID: 28833973 DOI: 10.1111/dth.12527] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
55 Weinstein JE, Pepple KL. Cytokines in uveitis. Curr Opin Ophthalmol 2018;29:267-74. [PMID: 29521875 DOI: 10.1097/ICU.0000000000000466] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
56 Ji H, Zhang N, Zhu M, Dong J, Jiang Z. Elevated Serum Immunoglobulin E Levels are Associated with the Severity of Newly Diagnosed, Acute Vogt-Koyanagi-Harada Disease. Curr Eye Res 2021;:1-5. [PMID: 34264155 DOI: 10.1080/02713683.2021.1951299] [Reference Citation Analysis]
57 Davies R, Carrasco R, Foster HE, Baildam EM, Chieng SEA, Davidson JE, Ioannou Y, Wedderburn LR, Thomson W, Hyrich KL. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS). Semin Arthritis Rheum 2016;46:190-5. [PMID: 27422803 DOI: 10.1016/j.semarthrit.2016.06.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
58 Leal I, Rodrigues FB, Sousa DC, Romão VC, Duarte GS, Carreño E, Dick AD, Marques-Neves C, Costa J, Fonseca JE. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review. Acta Ophthalmol 2018;96:e665-75. [PMID: 29577629 DOI: 10.1111/aos.13699] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
59 Barry RJ, Tallouzi MO, Bucknall N, Mathers JM, Murray PI, Calvert MJ, Moore DJ, Denniston AK. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. Cochrane Database Syst Rev 2018;12:CD012577. [PMID: 30562409 DOI: 10.1002/14651858.CD012577.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
60 Olivieri I, Accorinti M, Abicca I, Bisceglia P, Cimino L, Latanza L, Leccese P, Lubrano E, Marchesoni A, Miserocchi E, Neri P, Salvarani C, Scarpa R, D’angelo S; On behalf of the CORE Study Group. Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement. Rheumatol Int 2018;38:1727-34. [DOI: 10.1007/s00296-018-4094-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Diwo E, Sève P, Trad S, Bielefeld P, Sène D, Abad S, Brézin A, Quartier P, Koné Paut I, Weber M, Chiquet C, Errera MH, Sellam J, Cacoub P, Kaplanski G, Kodjikian L, Bodaghi B, Saadoun D. [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel]. Rev Med Interne 2018;39:687-98. [PMID: 29610003 DOI: 10.1016/j.revmed.2018.03.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Andersen V, Holmskov U, Sørensen SB, Jawhara M, Andersen KW, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, Fredberg U, Villadsen JA, Kjær SG, Fallingborg J, Moghadd SAGR, Knudsen T, Brodersen J, Frøjk J, Dahlerup JF, Nielsen OH, Christensen R, Bojesen AB, Sorensen GL, Thiel S, Færgeman NJ, Brandslund I, Stensballe A, Schmidt EB, Franke A, Ellinghaus D, Rosenstiel P, Raes J, Heitmann B, Boye M, Nielsen CL, Werner L, Kjeldsen J, Ellingsen T. A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine. Nutrients 2017;9:E499. [PMID: 28505128 DOI: 10.3390/nu9050499] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
63 Lazarević D, Nikolić I, Ratković-Janković M, Vojinović J. Outcome of Juvenile Idiopathic Arthritis Associated Uveitis in Two Disease Subtypes. Arch Rheumatol 2017;32:26-31. [PMID: 30375520 DOI: 10.5606/ArchRheumatol.2017.6060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
64 Pakdel F, Haghighi A, Pirmarzdashti N. Disease modifying drugs in idiopathic sclerosing orbital inflammatory syndrome. Orbit 2021;:1-10. [PMID: 34030586 DOI: 10.1080/01676830.2021.1929338] [Reference Citation Analysis]